Last reviewed · How we verify
Centro Medico Nacional La Raza, IMSS — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Diazepam Injectable Solution | Diazepam Injectable Solution | marketed | Benzodiazepine | GABA-A receptor | Neurology, Psychiatry, Critical Care |
Therapeutic area mix
- Neurology, Psychiatry, Critical Care · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ajenat Pharms · 1 shared drug class
- Assaf-Harofeh Medical Center · 1 shared drug class
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
- B.P. Koirala Institute of Health Sciences · 1 shared drug class
- Bausch Health · 1 shared drug class
- Chang Gung Memorial Hospital · 1 shared drug class
- Consorci Sanitari de l'Anoia · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Centro Medico Nacional La Raza, IMSS:
- Centro Medico Nacional La Raza, IMSS pipeline updates — RSS
- Centro Medico Nacional La Raza, IMSS pipeline updates — Atom
- Centro Medico Nacional La Raza, IMSS pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Centro Medico Nacional La Raza, IMSS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centro-medico-nacional-la-raza-imss. Accessed 2026-05-17.